Spasticity Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Huons, Supernus Pharma, Sun Pharma, Acorda

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spasticity pipeline constitutes 20+ key companies continuously working towards developing 20+ Spasticity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Spasticity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.


Spasticity Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spasticity Market.


Some of the key takeaways from the Spasticity Pipeline Report:

Companies across the globe are diligently working toward developing novel Spasticity treatment therapies with a considerable amount of success over the years. 
Spasticity companies working in the treatment market are Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Inc., Medtronic Neuro, Daewoong Pharma, and others, are developing therapies for the Spasticity treatment 

Emerging Spasticity therapies in the different phases of clinical trials are- Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, and others are expected to have a significant impact on the Spasticity market in the coming years.   
In July 2021, In order to assess the safety and effectiveness of HU-014 Inj in the treatment of post-stroke upper limb spasticity, Huons started a multi-center, Phase III clinical research. Five upper limb muscles received injections of HU-014 Inj (a total of 360 U/, IM). The experiment is currently recruiting volunteers and is expected to be finished by November 2022 with 198 participants.
In April 2021, The acquisition of an exclusive licence to register, sell, and commercialise botulinum toxin in the United States and Canada by Aquavit Holdings LLC was announced. Through a recent clinical research, Aquavit demonstrated the efficacy and safety of its proprietary delivery technology and associated intellectual property for botulinum toxin.


Spasticity Overview

Spasticity is a disorder marked by an unnatural rise in muscular tone or stiffness, which may impair speech or movement and be accompanied by discomfort or pain. Damage to the nerve pathways in the brain or spinal cord that regulate muscle action is the usual cause of spasticity.


Get a Free Sample PDF Report to know more about Spasticity Pipeline Therapeutic Assessment-


Emerging Spasticity Drugs Under Different Phases of Clinical Development Include:

Lu AG06466: Lundbeck
DAXXIFY: Revance Therapeutics
IPN10200: Ipsen
HU-014: Huons
SL-1002: Saol Therapeutics Inc
MYOBLOC: Supernus Pharma
SPARC1103: Sun Pharma
Tizanidine: Acorda Therapeutics
botulinum A toxin: Merz Pharmaceuticals GmbH
CORETOX®: Medy-Tox
XP19986 SR1: XenoPort, Inc.
intrathecal baclofen: MedtronicNeuro


Spasticity Route of Administration

Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 



Spasticity Molecule Type

Spasticity Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Small molecule
Gene therapy 


Spasticity Pipeline Therapeutics Assessment

Spasticity Assessment by Product Type
Spasticity By Stage and Product Type
Spasticity Assessment by Route of Administration
Spasticity By Stage and Route of Administration
Spasticity Assessment by Molecule Type
Spasticity by Stage and Molecule Type


DelveInsight’s Spasticity Report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration


Further Spasticity product details are provided in the report. Download the Spasticity pipeline report to learn more about the emerging Spasticity therapies


Spasticity Pipeline Analysis:

The Spasticity pipeline report provides insights into 

 The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.
Spasticity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.


Download Sample PDF Report to know more about Spasticity drugs and therapies


Spasticity Pipeline Market Drivers

Increasing prevalence of stroke, multiple sclerosis, and brain injury drive the market, increasing R&D for developing effective therapies are some of the important factors that are fueling the Spasticity Market.


Spasticity Pipeline Market Barriers

However, high cost of the treatment, lack of disease awareness in emerging economies and other factors are creating obstacles in the Spasticity Market growth.


Scope of Spasticity Pipeline Drug Insight    

Coverage: Global
Key Spasticity Companies: Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Supernus Pharma, Sun Pharma, Acorda Therapeutics, Merz Pharmaceuticals GmbH, Medy-Tox, XenoPort, Inc., Medtronic Neuro, Daewoong Pharma, and others
Key Spasticity Therapies: Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, MYOBLOC, SPARC1103, Tizanidine, CORETOX®, XP19986 SR1, intrathecal baclofen, Botulinum toxin type A, and others
Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies
Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers 


Request for Sample PDF Report for Spasticity Pipeline Assessment and clinical trials


Table of Contents 

1. Spasticity Report Introduction

2. Spasticity Executive Summary

3. Spasticity Overview

4. Spasticity- Analytical Perspective In-depth Commercial Assessment

5. Spasticity Pipeline Therapeutics

6. Spasticity Late Stage Products (Phase II/III)

7. Spasticity Mid Stage Products (Phase II)

8. Spasticity Early Stage Products (Phase I)

9. Spasticity Preclinical Stage Products

10. Spasticity Therapeutics Assessment

11. Spasticity Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spasticity Key Companies

14. Spasticity Key Products

15. Spasticity Unmet Needs

16 . Spasticity Market Drivers and Barriers

17. Spasticity Future Perspectives and Conclusion

18. Spasticity Analyst Views

19. Appendix

20. About DelveInsight


About DelveInsight


DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

%d bloggers like this: